Valneva’s Stock Plummets After Chikungunya Vaccine Withdrawal, Eyes Lyme Program
Valneva’s stock falls after US chikungunya vaccine withdrawal; company pivots to Lyme vaccine with Pfizer to restore investor confidence.
2 minutes to read
Valneva SE
Valneva Pulls Chikungunya Vaccine, Shifts to Lyme Disease with Pfizer Partnership
Valneva drops its U.S. Chikungunya vaccine plans, shares tumble, and it pivots to a promising Lyme‑disease partnership with Pfizer—what this means for investors.
3 minutes to read
Valneva SE Navigates Financial Challenges and FDA Decisions Amid Vaccine Development Successes
Valneva SE, a French biotechnology company, navigated a challenging year with opportunities for growth, despite financial losses and regulatory hurdles, as it continues to develop vaccines for infectious diseases.
3 minutes to read
EMA Lifts Restriction on Valneva’s Chikungunya Vaccine for Elderly, Balancing Risks and Benefits
The European Medicines Agency (EMA) has lifted its temporary restriction on Valneva’s chikungunya vaccine, IXCHIQ, for individuals aged 65 and above, allowing its use in vulnerable populations.
2 minutes to read